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ABSTRACT
Objective The gut microbiota, which is considered
a causal factor in metabolic diseases as shown best in
animals, is under the dual influence of the host genome
and nutritional environment. This study investigated
whether the gut microbiota per se, aside from changes
in genetic background and diet, could sign different
metabolic phenotypes in mice.
Methods The unique animal model of metabolic
adaptation was used, whereby C57Bl/6 male mice fed
a high-fat carbohydrate-free diet (HFD) became either
diabetic (HFD diabetic, HFD-D) or resisted diabetes (HFD
diabetes-resistant, HFD-DR). Pyrosequencing of the gut
microbiota was carried out to profile the gut microbial
community of different metabolic phenotypes.
Inflammation, gut permeability, features of white adipose
tissue, liver and skeletal muscle were studied.
Furthermore, to modify the gut microbiota directly, an
additional group of mice was given a gluco-
oligosaccharide (GOS)-supplemented HFD (HFD+GOS).
Results Despite the mice having the same genetic
background and nutritional status, a gut microbial profile
specific to each metabolic phenotype was identified. The
HFD-D gut microbial profile was associated with
increased gut permeability linked to increased
endotoxaemia and to a dramatic increase in cell number
in the stroma vascular fraction from visceral white
adipose tissue. Most of the physiological characteristics
of the HFD-fed mice were modulated when gut
microbiota was intentionally modified by GOS dietary
fibres.
Conclusions The gut microbiota is a signature of the
metabolic phenotypes independent of differences in host
genetic background and diet.
INTRODUCTION
The increasing fat-to-fibre ratio in the Western diet
is now considered among the major triggering
factors of metabolic impairments such as obesity
and type II diabetes.1 2 Using axenic mice,3e6 a key
advancement has been made during the last decade
when the gut microbiota was first associated with,
and then causally involved in, the regulation of
metabolic diseases. Furthermore, next generation
sequencing techniques have allowed a more
detailed study of gut microbes by avoiding labora-
tory cultivation. Pyrosequencing has permitted the
identification of the so-called ‘bacterial signature’ of
obesitydan increased Firmicutes to Bacteroidetes
ratio in humans7 and mice.8
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Significance of this study
What is already known about this subject?
< Gut microbiota alterations have been shown to
be associated and causally linked to metabolic
diseases such as type II diabetes and obesity in
humans and mice.
< A high-fat diet is able to unbalance the gut
microbiota and impair the gut barrier resulting in
increased endotoxaemia and metabolic diseases
in mice.
< A core gut microbiome has been shown to exist
and divergences from this core define a healthy
(ie, lean) versus diseased (ie, obese) status.
What are the new findings?
< A change in the ratio of Firmicutes to
Bacteroidetes characterises the different meta-
bolic phenotypes independently from the genetic
background or the diet during the metabolic
adaptation of mice to the dietary treatment.
< Direct treatment of the gut microbiota using
dietary fibres (gluco-oligosaccharide) affects the
metabolic adaptation of the mice independently
from their genetic background or their diet.
< Different gut microbial community profiles can
sign the same metabolic phenotype such as the
resistance to diabetes.
< Gut physiology and white adipose tissue mainly
affect the responsiveness of mice to the high-fat
diet independently from their genetic back-
ground or the diet.
How might it impact on clinical practice in the
foreseeable future?
< Bacterial markers could predict the occurrence
of a given metabolic phenotype (ie, diabetes)
and, furthermore, the treatment of apparently
healthy patients with nutritional additives
targeting intestinal microbiota might prevent
the occurrence of metabolic diseases indepen-
dently from risk factors such as a fat-enriched
diet or a genetic background.
doi:10.1136/gutjnl-2011-301012
Gut microbiota
We were the first to link the gut microbiota to inflammation-
driven9 10 insulin resistance by showing the lipopolysaccharide
(LPS) as an initiator of metabolic impairment.11 A continuous
infusion of low-dose LPS induced low-grade chronic inflamma-
tion and most of the features of the early onset of metabolic
diseases such as visceral fat deposition, glucose intolerance and
hepatic insulin resistance.11 Several studies subsequently
showed gut microbiota-driven modifications of white adipose
tissue (WAT) plasticity by regulating fat storage,12 energy
harvesting,13 diet-induced obesity14 and adiposity,15 presenting
WAT as a major target of gut microbes.
However, both the genetic background of the host and the
dietary environment are responsible for the occurrence of
metabolic diseases by shaping the gut microbiota, even if this
concept can be challenged by the notion of diabetic-sensitive and
diabetic-resistant mice.16 We first showed that, in inbred male
C57Bl/6 mice fed a high-fat carbohydrate-free diet (HFD) for
9 months, most of the mice became diabetic and obese but some
remained lean and non-diabetic or diabetic but with a lean
phenotype.16 Importantly, the metabolism of each phenotype
was different, showing that, despite an unchanged genetic
background and diet, a metabolic adaptation occurred. We
therefore postulated that a different gut microbiota could be
associated with the metabolic phenotypes. In this study we
focus on the occurrence of diabetes, without obesity as
a confounding factor, by pyrosequencing gut microbiota from
mice fed a HFD for 3 months and comparing lean diabetes-
sensitive (HFD-D) mice with lean diabetes-resistant (HFD-DR)
mice. Moreover, to understand whether the gut microbiota
directly affected the metabolic phenotypes, another group of
mice was given a gluco-oligosaccharide (GOS)-supplemented
HFD (HFD+GOS) for 3 months. Our results showed that
a phenotype-specific gut microbiota signature exists, character-
ising the metabolic heterogeneity of mice aside from changes in
genetic background and diet.
MATERIALS AND METHODS
Animal model and dietary treatment
A cohort of 100 C57Bl/6 4-week-old male mice was fed a HFD
(approximately 72% fat (corn oil and lard), 28% protein and <1%
carbohydrate; SAFE, Augy, France) for 3 months. In addition,
another group of 10 mice was fed a a1-2-GlucoOligoSaccharide17
(O-a-D-glcp(1-2)-O-a-D-glcp(1-6)n-O-a-D-glcp(1e4) where (2<n
<7), GOS)-supplemented HFD (500 mg/mouse/day, 10% of daily
intake) (HFD+GOS) for 3 months. Mice were group-housed (five
mice per cage) in a controlled environment (inverted 12 h
daylight-cycle, light off at 10:00 h). Mice were fasted for 6 h and
killed by cervical dislocation; the tissues were collected and snap-
frozen in liquid nitrogen. All animal experimental procedures were
approved by the local ethical committee of Rangueil University
Hospital (Toulouse).
Glucose tolerance test, plasma non-esterified fatty acids and
triglyceride
After 3 months of HFD, an intraperitoneal glucose tolerance test
(IPGTT) was performed to phenotype the mice as diabetes
resistant (HFD-DR) or diabetic (HFD-D). Briefly, mice fasted for
6 h were injected with glucose (1 g/kg) into the peritoneal cavity
as previously described.11
Plasma levels of non-esterified fatty acids (NEFA) and triglyc-
erides were measured using commercial kits (Wako Diagnostics,
Richmond, Virginia, USA and Triglycerides enzymatiques PAP
150, Biomerieux, Marcy l’Etoile, France, respectively).
Luminex analysis
Simultaneous ELISA assays (tumour necrosis factor a (TNFa),
interleukin 6 (IL-6), plasminogen activator inhibitor 1 (PAI-1),
insulin, leptin, resistin) were performed with 10 ml plasma and
analysed by a continuous flux fluorimeter using Multiplex
Immunoassays, Xmap technology (Luminex Corporation,
Austin, Texas, USA).
WAT morphometry and F4/80 staining
Adipocyte numbers were classified according to size, estimated
by a point counting technique on paraffin-embedded H&E
counterstained sections, and expressed as a percentage of the
total population counted, as previously described.11 The total
count ranged from 3275 to 7052 cells per condition. The mean
surface area (mm2) of the adipocytes was calculated using image
analyser software (ImageJ). F4/80 staining was performed as
follows. Ethanol-fixed paraffin-embedded adipose tissue sections
were deparaffinised and rehydrated. Sections were blocked
in normal serum and incubated overnight with primary rat anti-
mouse F4/80 monoclonal antibody (1/1000; Serotec, Oxford,
UK). Endogenous peroxidase activity was quenched when
incubated with 3% hydrogen peroxide for 20 min. Secondary
antibody staining was done using goat anti-rat biotinylated
Ig antibody (1/500, 30 min, room temperature (RT)) and strep-
tavidin-conjugated horseradish peroxidase (1/500, 30 min, RT)
and detected with 3,39-diaminobenzidine. Sections were
counterstained with haematoxylin before dehydration and
coverslip placement. The number of F4/80 positive cells per
microscope field was counted and divided by the total number
of adipocytes in the section; 5e12 fields were counted per
sample.
FACS analysis
Cells from the stroma vascular fraction (SVF) were obtained after
collagenase digestion of fresh mouse visceral WAT, as previously
described.18 Murine SVF cells (100 000 cells) were incubated
with fluorescein isothiocyanate (FITC)-conjugated antibodies
(CD4, F4/80), PE-conjugated antibodies (CD3, CD34), PercP-
Cy5.5-conjugated antibody (CD11b), APC-conjugated antibody
(CD8, CD31) or respective isotype controls. Analyses were
performed using a FACS Calibur flow cytometer as previously
described.18
DNA denaturing gradient gel electrophoresis (DNA DGGE)
Total DNAwas extracted from frozen caecum contents using the
TriPure reagent (Roche Diagnostics, Meylan, France) according to
the manufacturer ’s protocol. 200 ng DNAwere amplified by PCR
using a Taq Polymerase (Sigma Aldrich, St Louis, Missouri, USA)
and 300 nM denaturing gradient gel electrophoresis (DGGE)-
specific 16S rRNA universal primers (forward primer 59-CG
CCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGGGG-
AC TCCTACGGGAGGCAGCAGT-39; reverse primer 59-GTATTA
CCGCGGCTGCTGGCAC-39), carrying (forward primer only)
a GC-enriched region (GC clamp), generating 233 bp amplicons.
The size of the latter was checked by 2% agarose gel electropho-
resis. 80 ng of amplicons were loaded on 8% acrylamide gel with
a 35e55% (w/v) urea denaturant gradient. The gels were run
overnight in TAE 1X at 608C. The following day the gels were
stained for 30 min in TAE 1X-SYBR safe DNA gel staining and
scanned with a Typhoon 9400 instrument (Amersham Biosci-
ences, GE Healthcare Europe GmbH Branch France, Velizy-Villa-
coublay, France). The band profile was analysed using
PermutMatrixEN software Version 1.9.3.0.19
RNA extraction and real-time PCR
Total RNA was extracted from frozen subcutaneous or visceral
WATusing the RNeasy mini kit (Qiagen, Courtaboeuf, France).
500 ng RNA were retrotranscripted for 2 h at 378C using
Superscript II reverse transcriptase (Invitrogen, Cergy Pontoise,
France) with random hexamers. Real-time PCR was performed
with 12.5 ng cDNA and 900 or 300 nM concentrations of
forward and reverse primers in a final volume of 20 ml using the
SYBR green or TaqMan Universal PCR Master Mix (Applied
Biosystems, Courtaboeuf, France). Fluorescence was monitored
and analysed in a GeneAmp 7500 detection system instrument
(Applied Biosystems). Analysis of the 18S ribosomal RNA was
done in parallel using the primers and probe of the ribosomal
RNA control Taqman Assay Kit (Applied Biosystems) to
normalise gene expression. The results are expressed as
2(Ct18S-Ctgene), where Ct corresponds to the number of cycles
needed to generate a fluorescent signal above a predefined
threshold. Primers were designed using the Primer Express
software (Applied Biosystems).
Bacterial RT-PCR
Total RNAwas extracted from frozen caecum contents using the
TriPure reagent according to the manufacturer ’s protocol. 1 mg
total RNA was retrotranscripted for 2 h at 378C using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Villebon-sur-Yvette, France). 10 ng cDNA were amplified using
sense and antisense primers at a concentration of 300 nM and
the Power SYBR Green PCR Master Mix (Applied Biosystems).
The bacterial primer sequences are reported in table 2 in the
online supplement.
Gut paracellular permeability assay
Ileum, caecum and colon were collected from fed mice and strips
mounted in Easymount Ussing-type chambers (Physiologic
Instruments, San Diego, California, USA) with a flux area of
0.3 cm2, as previously described.20 After 15 min, one-fifth of the
initial volume of the apical compartment (mucosal side) buffer
solution was replaced with FITC-labelled dextran (4000 Da,
0.022 g/ml, Sigma). After 1 h the fluorescent intensity was
measured on the serosal side of the chamber.
Protein extraction and western blot analysis
WAT, liver and skeletal muscle lysates were prepared as described
elsewhere.21 The following antibodies were used: pSer536NF-kB,
NF-kB, pSer2448mTOR, mTOR, pSer307IRS-1, IRS-1, IRS-2,
pSer473Akt, Akt, b-actin, pThr172AMPKa, AMPK, pSer79ACC,
ACC, pSer9GSK-3b, GSK-3b, pThr183/Tyr185SAPK/JNK, SAPK/
JNK, SOCS-3 (Cell Signaling Technology, Ozyme, Saint
Quentin, France), PKCe and PKCq (Santa Cruz, Heidelberg,
Germany).
Intestinal tight junction proteins: western blot analysis
Ileal and caecal samples were homogenised in RIPA buffer (1%
Igepal, 0.5% deoxycholic acid, and 0.1% SDS in Tris buffered
saline solution 1X, pH 7.4) with protease inhibitors (Roche
Diagnostics, Meylan, France) and centrifuged at 10 000g for
10 min (48C). Protein concentrations were assayed using the BC
Assay Uptima kit (Interchim, Montluçon, France). Equal
amounts of protein per lane were separated by SDS-PAGE and
transferred onto nitrocellulose membranes (Optitran, Schleicher
1 Schuell Biosciences, Dassel, Germany). Membranes were
blocked with 5% dry milk or 10% FCS in 0.1% Tween in TBS
(TBS-T) for 2 h (RT) and then incubated overnight at 48C with
primary antibodies. Immunoblotting was performed using
polyclonal rabbit anti-occludin antibody (Zymed Laboratories,
South San Francisco, California, USA) diluted 1:500 in 5% dry
milk in TBS-T or polyclonal rabbit anti-ZO-1 (Zymed Labora-
tories) diluted 1:1000 or anti-GAPDH (Cell Signaling) diluted
1:1000 or anti-JAM-A (Abcam, Cambridge, UK) diluted 1:2500
in 10% FCS in TBS-T. After washing in TBS-T the membranes
were incubated for 1 h at RTwith secondary antibodies conju-
gated to IRDye 800CW (Li-COR). After washing again in TBS-T
the membranes were briefly rinsed in TBS and scanned and
analysed by an Odyssey IR scanner using Odyssey imaging
software 3.0. Scan settings were medium or high image quality,
169 mm resolution and intensity 3.0e6.0 for both channels with
no offset. Antibody signals were analysed as integrated inten-
sities of regions defined around the bands of interest in either
channel.
Pyrosequencing
Extraction and amplification of DNA
DNA was extracted from frozen caecum contents using the
QIAamp DNA mini stool kit (Qiagen, Courtaboeuf, France),
slightly modified by adding a bead (#106 mm diameter) beating
step (6500 rpm, 3330 s). 200 ng DNA were amplified by PCR
using the Pfu DNA Polymerase (Fermentas, Saint-Rémy-lès
-Chevreuse, France). The 16S rRNA V2 region was targeted by
using the forward primer 8F 59-AGAGTTTGATCMTGGCT
CAG-39 and reverse primer 338R 59-GCTGCCTCCCGTAGGA
GT-39.22 Pyrosequencing was carried out on a multiplexed GS FLX-
Ti, following the manufacturer ’s recommendations (454 Life
Sciences, Roche). Six mice per group were sequenced in six runs
(three mice per run).
Bioinformatic analysis
2 969 179, 2 533 380 and 2 403 166 raw sequence reads were first
processed with 16SCleaner (https://mulcyber.toulouse.inra.fr/
plugins/mediawiki/wiki/ng6/index.php/16Scleaner) to yield
a total of 2 059 967, 1 479 791 and 1 591 906 reads from the HFD-
DR, HFD-D and HFD+GOS groups, respectively. The Mothur
package23 was used, following the Costello stool analysis pipe-
line (http://www.mothur.org/wiki/Costello_stool_analysis), to
further filter reads and generate taxonomic classification infor-
mation (using the Silva database, http://www.arb-silva.de/) for
a final set of 1 626 411, 959 215 and 1 182 616 reads. Permut-
MatrixEN software version 1.9.3.019 was used to identify
clusters at the level of both mice groups and taxa.
Statistical analysis
The results are presented as means 6 SEM. Statistical analysis
was performed by one-way or two-way ANOVA followed by
post hoc tests (Tukey or Bonferroni test, as reported) or by
unpaired Student t test, using GraphPad Prism Version 5.00 for
Windows Vista (GraphPad Software, San Diego, California,
USA). p Values <0.05 were considered significant.
RESULTS
Metabolic adaptation to high-fat feeding after 3 months
To test whether metabolic phenotypes in HFD-fed mice were
linked to a specific gut microbial signature, 100 4-week-old
C57Bl/6 male mice were fed a diabetogenic/non-obesogenic
carbohydrate-free (<1%) HFD for 3 months (figure 1A). An
IPGTT was then performed and the mice were separated
according to their resistance (HFD-DR) or sensitivity (HFD-D)
to HFD-induced diabetes. HFD-D mice were characterised by
Gut microbiota
higher glycaemia at all time points compared with HFD-DR
mice (figure 1B), as also shown by the glycaemic index (figure
1C). To modify the gut microbiota directly, an additional group
of 10 mice was fed HFD+GOS for 3 months. HFD+GOS mice
showed a similar degree of glucose tolerance to HFD-DR mice
(figure 1B,C) and to previously published results in a different
glucose-intolerant model.24
Analysis of multiple metabolic parameters
The metabolic adaptation to HFD was associated with
numerous metabolic parameters. In plasma, fasting levels of
NEFA increased in HFD-DR mice compared with HFD-D and
HFD+GOS mice (see table 1 in online supplement). Conversely,
plasma fasting and fed triglyceride levels increased in HFD-D
mice compared with HFD-DR and HFD+GOS mice (see table 1
in online supplement). Fasting insulin was lower in HFD-D and
HFD+GOS mice than in HFD-DR mice, whereas fed insulin
levels did not vary significantly (see table 1 in online supple-
ment). Body weight was recorded twice per month to ensure
a lack of diet-induced obesity. As expected, no statistically
significant change was observed (HFD-DR 26.560.3 g, HFD-D
27.860.3 g, HFD+GOS 28.460.4 g; p>0.05).
Metabolic adaptation to HFD is associated with metabolic
phenotype-specific gut microbiota
To investigate the gut microbiota from metabolic phenotypes
we first performed a DGGE on subsets of three mice per group as
a primary validation of our hypothesis. DGGE data showed that
the intestinal microbial profiles were considerably different
among all metabolic phenotypes (see figure 2 in online supple-
ment). Importantly, it was possible to cluster the three meta-
bolic phenotypes according to Pearson tree analysis. However,
HFD-DR and HFD-D mice were still characterised by some
degree of similarity. Conversely, the gut microbial profile of HFD
+GOS mice was even more different from HFD-DR and HFD-D
mice (see figure 2 in online supplement).
We next quantified living bacteria in the caecum. Since up to
90% of gut microbiota is composed of Firmicutes and Bacter-
oidetes (two major bacterial phyla), we focused mostly on
bacteria from these divisions. Quantitative RT-PCR was used
to measure the 16S rRNA concentration of bacteria found
modulated during altered metabolism (see table 2 in online
supplement). The results showed that the microbial composi-
tion varied according to the different metabolic phenotypes. The
main significant differences between HFD-D and HFD-DR mice
concerned the C leptum cluster IV (figure 3A in online supple-
ment), Enterococcus spp (figure 3C in online supplement) and
Nitrospira spp (figure 3D in online supplement), which were
significantly decreased in HFD-D mice compared with HFD-DR
mice. Interestingly, GOS supplementation of HFD generally
reduced the count of the overall bacteria analysed except Bifi-
dobacterium spp (figure 4A in online supplement) and Bacteroides
prevotella (figure 4C in online supplement), although the differ-
ences were not statistically significant (p¼0.098 and p¼0.099,
respectively).
Pyrosequencing of the gut microbiota identifies bacterial genera
associated with metabolic phenotypes
To analyse the metagenomic signature, the overall caecal
microbiota from each metabolic phenotype was sequenced. The
operational taxonomic unit (OTU) count was higher in HFD-D
mice than in HFD-DR mice while the read counts varied in the
opposite direction (figure 1A,B in online supplement). Impor-
tantly, GOS treatment affected both parameters.
The data also showed an inverted Bacteroidetes to Firmicutes
ratio between HFD-D and HFD-DR mice (figure 2A). We then
analysed the corresponding families and genera in more detail.
The Lachnospiraceae family (Firmicutes) was reduced by 28% in
the HFD-D group compared with the HFD-DR group (figure
2C). In addition, the Oscillibacter genus was also reduced by 54%
(figure 3A). The Ruminococcaceae family (Firmicutes) was
slightly reduced (2%) in HFD-D mice compared with HFD-DR
mice (figure 2C).
Within the Bacteroidetes, the proportion of the S24-7 family
almost tripled in the HFD-D group (figure 2D) as well as the
Deferribacteres phylum (figure 2B). Furthermore, the genus
Parasutterella remained unchanged and the Helicobacter genus
(both Proteobacteria) was dramatically reduced (figure 3D).
Interestingly, the Bacteroidetes to Firmicutes ratio was
dramatically increased in HFD+GOS mice and the Actino-
bacteria phylum almost totally disappeared (0.1%) (figure 2A).
Altogether, numerous other families and genera were affected.
In particular, HFD+GOS mice had increased S24-7 family
Figure 1 Metabolic adaptation after
3 months of high-fat diet (HFD) and
change in phenotype by
supplementation of HFD with gluco-
oligosaccharides (GOS). (A) Timeline of
the experimental protocol. (B)
Intraperitoneal glucose tolerance test
(IPGTT) in HFD-fed mice that became
diabetic (HFD-D, closed squares,
n¼24), diabetes-resistant (HFD-DR,
open squares, n¼10) or fed a GOS-
supplemented HFD (HFD+GOS, closed
triangles, n¼10). Data are shown as
mean 6 SEM; *p<0.05, ***p<0.001
(HFD-D vs HFD-DR) and xxxp<0.001
(HFD-D vs HFD+GOS) (two-ANOVA
and Bonferroni post test). (C) Glycaemic
index; ***p<0.001 (unpaired Student
t test).
Gut microbiota
(figure 2D) and Parabacteroidetes genus (figure 3B) whereas the
Coriobacteriaceae family (figure 2E) andOlsenella (figure 3C) and
the Mucispirillum genera (figure 3E) disappeared. The gut
microbial signature of each metabolic phenotype is summarised
in figure 4.
Plasma inflammation and gut paracellular permeability are
associated with metabolic phenotypes
To further determine whether changes in the gut microbiota
could be associated with bacterial inflammatory factors, we
measured the plasma concentration of LPS. Fasting LPS plasma
Figure 2 Caecum microbial profiles vary according to metabolic phenotypes. Pyrosequencing analysis of (A, B) phyla and (CeE) taxa families in mice
fed a high-fat diet (HFD) which became diabetic (HFD-D) or diabetes-resistant (HFD-DR) or mice fed HFD supplemented with gluco-oligosaccharides
(HFD+GOS). Data are shown as a percentage of the total identified sequences per group.
Gut microbiota
levels increased in HFD-D mice compared with HFD-DR mice
but were reduced when the gut microbiota was challenged by
GOS treatment (figure 5A). Measurement of circulating cyto-
kines showed that, of the cytokines TNFa, IL-6 and PAI-1, the
latter was significantly increased in HFD-D mice compared with
HFD-DR mice and GOS treatment significantly modified this
parameter (figure 5B).
To understand whether a different endotoxaemia could be
related to altered gut permeability, as already reported,4 we
measured permeability using Ussing’s chambers. Paracellular
permeability in the ileum and caecum was significantly increased
in HFD-D mice compared with all the other groups (figure 5C,D),
but not significantly (p>0.05) in the colon (figure 5E). In the
ileum this was coupled to a reduction in occludin and junctional
Figure 3 Caecum microbial genera of different metabolic phenotypes. (A-E) Pyrosequencing of genera in mice fed a high-fat diet (HFD) that became
diabetic (HFD-D), diabetes-resistant (HFD-DR) or mice fed a diet supplemented with gluco-oligosaccharides (HFD+GOS). Data are shown as
a percentage of the total identified sequences per group.
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adhesion molecule A (JAM-A) compared with HFD-DR mice but
not ZO-1 (p>0.05, figure 5A in online supplement). Conversely,
HFD+GOS mice showed an increase in all the studied proteins
compared with the other groups (figure 5A in online supple-
ment). Similar results were obtained in the caecum, except for
ZO-1 which did not vary significantly (p>0.05) between all the
groups (figure 5B in online supplement).
WAT and metabolic adaptation
We then focused on subcutaneous and visceral WAT as a major
target of gut microbiota.12e15 The weight of both subcutaneous
and visceral WAT depots increased in HFD-D mice compared
with HFD-DR mice. GOS treatment prevented this increase
(figure 6A in online supplement). Plasma leptin and resistin were
increased in the HFD-D metabolic phenotype as well as subcu-
taneous mRNA concentrations of both, and the increases were
prevented by GOS treatment (figure 6B,C in online supplement).
Apelin expression was increased in HFD-D subcutaneous and
visceral WATwhereas the adiponectin mRNA was not changed
in any group (figures 6D and 7B in online supplement).
In all the groups the mRNA concentration of metabolic genes
(GLUT4, FAS, AP2) was similar (p>0.05; figures 6E and 7C in
online supplement). No relevant differences (p>0.05) were
observed in inflammatory marker mRNAs among all groups in
subcutaneous (figure 6F in online supplement) or visceral WAT
(figure 7D in online supplement).
The adipocyte area increased in HFD-D mice compared with
HFD-DR mice but GOS treatment did not significantly affect
this parameter (p>0.05, figure 6A,B). Subsequently, cells from
the SVF were isolated and studied by FACS analysis. The total
SVF cell number was increased in HFD-D mice compared with
HFD-DR mice and GOS treatment prevented the occurrence of
the diabetic metabolic phenotype (figure 6C). Furthermore, we
characterised different SVF cell populations. Preadipocytes,
macrophages and lymphocytes were increased in the HFD-D
group compared with the HFD-DR group. HFD+GOS mice had
a reduced overall lymphocyte cell count (notably T lympho-
cytes) compared with HFD-DR mice, although the difference
was not statistically significant (figure 6D).
Immunohistochemistry confirmed the FACS data, showing
a significant increased percentage of macrophages per adipocyte
count in HFD-D mice compared with HFD-DR mice and
no significant differences compared with HFD+GOS mice
(figure 6E).
In agreement with increased immunoinflammatory cell
accumulation, both NF-kB and mTOR phosphorylation
Figure 4 Cluster identification of gut microbial profiles of the different metabolic phenotypes: (A) phyla, (B) families, (C) genera and (D) overall taxa
shown according to metabolic phenotypes for mice fed a high-fat diet (HFD) that became diabetic (HFD-D, closed squares), diabetes-resistant mice
(HFD-DR, open squares) and mice fed a diet supplemented with gluco-oligosaccharides (HFD+GOS, closed triangles). Pearson tree analysis was
performed to cluster groups (top) and taxa (left side) of each heat map.
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increased in HFD-D mice compared with HFD-DR mice.
Conversely, HFD+GOS mice showed a reduced non-significant
trend for NF-kB and a similar trend, but to a lesser extent, for
mTOR activation (figure 6F). In addition, no significant changes
(p>0.05) were observed in any groups in insulin signalling and
energy metabolic pathways, except for the activation of AKT
which was significantly increased in HFD+GOS mice compared
with HFD-D mice (figure 7 in online supplement).
Changes in the gut microbiota slightly affected liver and skeletal
muscle during metabolic adaptation
To determine whether the metabolic endotoxaemia also affected
other insulin-responsive organs, we quantified proteins involved
in liver and skeletal muscle metabolism. Notably, HFD-D mice
had a significant increase in liver weight compared with HFD-
DR mice (figure 7A). Surprisingly, HFD+GOS mice also showed
a significant increase in liver weight compared with HFD-DR
mice, and to the same extent as HFD-D mice (figure 7A).
Moreover, TNFa and IL-6 mRNA concentrations did not vary
significantly (p>0.05) whatever the group, whereas PAI-1
mRNA significantly increased in HFD-D mice compared with
HFD-DR and HFD+GOS mice (figure 7B). Surprisingly, liver
insulin (figure 7C), energy (figure 7D) and inflammatory path-
ways (figure 7E) did not show significant changes (p>0.05)
between all the groups.
We subsequently investigated skeletal muscle and found that
only TNFa mRNA increased in HFD-D mice compared with
HFD-DR and HFD+GOS mice (figure 8A in online supplement).
Again there were no major changes (p>0.05) in insulin, energy
and inflammatory pathways between all the groups (figure 8B in
online supplement).
DISCUSSION
In this study we have shown that diabetes-sensitive (HFD-D)
and diabetes-resistant (HFD-DR) metabolic phenotypes are
associated with a specific gut microbial profile, aside from
changes in genetic background and diet. Moreover, targeting the
gut microbiota of HFD-fed mice with dietary fibres prevented
the occurrence of the diabetic phenotype and showed a specific
microbial signature. Our data further corroborate increased gut
permeability and WAT plasticity during type II diabetes.
The microbial diversity of different metabolic phenotypes
displayed a wider variation in OTUs than read counts,
suggesting that a given metabolic phenotype (ie, HFD+GOS)
could be selecting specific bacterial populations (ie, Bacter-
oidetes), as shown for prebiotics.25 A meticulous examination
revealed that the Bacteroidetes to Firmicutes ratio increased in
the diabetic phenotype, confirming the results reported in
patients with type II diabetes26 but contrasting with findings
reported by Gordon et al.7 However, we aimed to study type II
diabetes per se, intentionally lacking obesity, which explains the
aforementioned mismatch. In fact, obesity has been shown as
a main driving factor of changes in the gut microbiome between
lean and obese twins where, despite different microbe assembly,
a core microbiome exists and divergence from it leads to
a pathological state (ie, lean vs obese).22
Figure 5 Plasma inflammation and gut paracellular permeability. (A) Fasting plasma lipopolysaccharide (LPS) levels, (B) cytokine concentrations in
plasma and (CeE) intestinal paracellular permeability in the ileum (C), caecum (D) and colon (E) in mice fed a high-fat diet (HFD) that became diabetic
(HFD-D), diabetes-resistant (HFD-DR) and in mice fed a diet supplemented with gluco-oligosaccharides (HFD+GOS). Data are shown as mean 6 SEM;
*p<0.05, **p<0.01 (unpaired Student t test; n¼6e12 per group). IL, interleukin; PAI-1, plasminogen activator inhibitor 1; TNFa, tumour necrosis
factor a.
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Figure 6 Cell architecture and inflammation in visceral white adipose tissue (WAT). (A) Adipocyte area and distribution, (B) mean adipocyte area, (C)
total cell count of the stroma vascular fraction (SVF)/g visceral WAT, (D) endothelial (CD31+), preadipocytes (CD34+), macrophages (F4/80/CD11b
+), total lymphocytes and T cells (CD3+), (E) macrophage immunostaining and number (%) per adipocyte count, (F) western blot analysis of
phosphorylated and total proteins involved in inflammatory pathways in mice fed a high-fat diet (HFD) which became diabetic (HFD-D), diabetes-
resistant (HFD-DR) and mice fed a diet supplemented with gluco-oligosaccharides (HFD+GOS). Data are shown as mean 6 SEM; *p<0.05,
**p<0.01, ***p<0.001 (unpaired Student t test; n¼5e12 per group).
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Indeed, we identified specific changes in genera (Oscillibacter,
Parabacteroidetes, Alistipes and Olsenella, Helicobacter and Mucis-
pirillum) as a signature of the metabolic phenotype. The reasons
for the changes in the gut microbiota remain unclear, despite
unchanged genetic background and diet. Furthermore, this result
is specifically linked to caecal microbiota. We cannot exclude the
possibility that a different outcome could have occurred in other
gut regions. A different food intake and/or the immune system
could also have contributed to shape the microbiota, as reported
in other studies.27e30 To determine whether gut microbiota is the
cause or consequence of the metabolic phenotypes, we specifi-
cally modified it with dietary fibres.25 31 This treatment
dramatically changed the gut microbiota and then the metabolic
phenotype, suggesting that it could be causal, although demon-
stration of the causality needs further evaluation in germ-free
mice. In addition, despite the diabetic state being normalised, the
HFD+GOS microbiota still remained different from the non-
diabetic HFD-DR mice, suggesting that several gut microbiota
profiles could be a signature for the same metabolic phenotype.
The pathophysiological mechanisms involved in the induction of
different metabolic phenotypes might differ. To gain some
information on the link between microbial profiles and metabolic
phenotypes we characterised numerous tissue features.
Our data suggest that the impact of the specific microbiota
was facilitated by increased gut permeability in both the ileum
and caecum of HFD-D mice, resulting in increased endotox-
aemia. This change could indeed dramatically affect metabolism
since the intestinal barrier plays a critical role in the transport of
nutrients and macromolecules and, at the same time, provides an
effective barrier to harmful macromolecules and microorgan-
isms.32 Loose tight junctions could therefore allow nutritional
and other microbial substances to cross the intestinal epithelium
and target WAT, resulting in increased adipokine production
(leptin and resistin), adipose cell size and SVF cell number, thus
confirming the literature.12e15
Conversely, neither liver nor skeletal muscle showed major
metabolic modulations besides an increased TNFa mRNA
concentration in HFD-D mice, suggesting that these organs do
not play a pivotal role during metabolic adaptation as an early
event shaping the metabolic phenotypes.
On the other hand, WAT is an important player in the control
of metabolic inflammation leading to insulin resistance.9 33 34
Here we show that HFD-D mice were characterised by a large
increase in SVF cell number. In addition, most of the cellular
populations including macrophages, preadipocytes and
lymphocytes tended to increase. Such changes could be
responsible for the diabetic phenotype under the control of the
gut microbiota, and may even explain the increased inflamma-
tory tone observed in HFD-D mice via the slight but significant
increased activation of NF-kB and mTOR pathways which are
upregulated during metabolic diseases.
We conclude that a specific gut microbiota, aside from changes
in genetic background and diet, is a signature of the different
metabolic phenotypes of ‘diabetic’ versus ‘diabetes-resistant’
during metabolic adaptation to HFD. We cannot exclude the
possibility that subtle changes in the microbiota occurred before
the HFD treatment and/or that epigenetic mechanisms could
have oriented a given phenotype. However, mice from the same
cage do not have completely similar gut microbiota (as occurs in
mono-colonised axenic mice).
Our data suggest that the gut microbiota could affect WAT
biology, essentially affecting the SVF. Consequently, modulating
Figure 7 Liver weight, inflammation,
insulin and energy pathways during
metabolic adaptation. (A) Liver weight;
(B) TNFa, IL-6 and PAI-1 mRNA
concentrations; (CeE) western blot
analysis of phosphorylated and total
proteins involved in (C) insulin
signalling, (D) energy metabolism and
(E) inflammation from mice fed a high-
fat diet (HFD) which became diabetic
(HFD-D), diabetes-resistant (HFD-DR) or
mice fed a diet supplemented with
gluco-oligosaccharides (HFD+GOS).
Data are shown as mean 6 SEM;
*p<0.05, ***p<0.001 (unpaired
Student t test; n¼4 per group). IL,
interleukin; PAI-1, plasminogen
activator inhibitor 1; TNFa, tumour
necrosis factor a.
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the gut microbiota by appropriate dietary fibres represents
a promising strategy to control or prevent metabolic diseases.
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